HYBIO(SZ:300199) Xin Lang Zheng Quan·2025-09-22 01:20Group 1 - On September 19, Hanyu Pharmaceutical experienced a decline of 2.74% with a trading volume of 1.232 billion yuan [1] - The financing data on the same day showed a financing purchase amount of 120 million yuan and a financing repayment of 159 million yuan, resulting in a net financing outflow of 38.83 million yuan [1] - As of September 19, the total balance of margin trading for Hanyu Pharmaceutical was 1.473 billion yuan, accounting for 6.91% of its circulating market value, which is above the 80th percentile of the past year [1] Group 2 - As of June 30, the number of shareholders for Hanyu Pharmaceutical reached 63,000, an increase of 9.95% compared to the previous period [2] - The company reported a revenue of 549 million yuan for the first half of 2025, representing a year-on-year growth of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a significant increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2]